Eli Lilly | LLY - Capital Social e Reservas





Capital Social e Reservas Alterar Data
AbbVie USD -6.66B 3.39B 2026-03
Abbott USD 52.06B 69M 2026-03
ALKERMES USD 1.75B 67.76M 2026-03
Amgen USD 9.19B 532M 2026-03
AstraZeneca USD 47.33B 1.33B 2026-03
Baxter International USD 6.04B 86M 2026-03
Biogen USD 18.65B 394.9M 2026-03
Bristol-Myers Squibb USD 20.07B 1.6B 2026-03
Coherus Biosciences USD 61.01M 26.76M 2025-12
Drreddys Laboratories INR 4.14B 107.72M 2025-12
Eli Lilly USD 31.2B 4.66B 2026-03
Gilead Sciences USD 23.52B 897M 2026-03
GlaxoSmithKline GBP 17.42B 1.05B 2026-03
Glaxosmithkline GBP 22.06B 360M 2025-12
J&J USD 81.19B 358M 2026-03
Medtronic USD 48.99B 128M 2025-12
Merck USD 45.88B 6.73B 2026-03
Neurocrine Biosciences USD 3.41B 154.3M 2026-03
Novartis USD 38.93B 7.2B 2026-03
Novartis USD 46.13B 1.8B 2025-12
Novo Nordisk DKK 203.07B 9.02B 2026-03
Perrigo USD 2.5B 436.7M 2026-03
Pfizer USD 90.1B 3.63B 2026-03
Phibro Animal Health USD 361.83M 29.47M 2026-03
Prestige Brands USD 1.89B 58.06M 2026-03
Regeneron Pharmaceuticals USD 31.42B 166.7M 2026-03
Roche Holding CHF 33.8B 758M 2025-12
Sanofi EUR 72.81B 1.1B 2026-03
Sanofi EUR 71.71B 14.25B 2025-12
United Therapeutics USD 5.9B 1.2B 2026-03
Zoetis USD 3.23B 98M 2026-03